| Bioactivity | Phenoxodiol (Idronoxil), a synthetic analog of Genestein, activates the mitochondrial caspase system, inhibits XIAP (an apoptosis inhibitor), and sensitizes the cancer cells to Fas-mediated apoptosis. Phenoxodiol also inhibits DNA topoisomerase II by stabilizing the cleavable complex. Phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle and upregulates p21WAF1 via a p53 independent manner[1][2]. | ||||||||||||
| Invitro | Phenoxodiol (Idronoxil) (0-10 μg/mL; 24 h) decreases cell viability of primary ovarian cancer cells[1].Phenoxodiol (0-10 μg/mL; 24 h) induces apoptosis and restores sensitivity to Fas-mediated apoptosis in ovarian cancer cells[1].Phenoxodiol (0-10 μg/mL; 24 h) induces caspase-8 activation and FLIP downregulation through the Akt-pathway. Phenoxodiol-induced apoptosis involves activation of the mitochondrial pathway and is caspase dependent. Phenoxodiol treatment results in downregulation and cleavage of XIAP[1].Phenoxodiol (10 and 30 μM; 24 and 48 h) induces cell cycle arrest in the G1/S phase of the cell cycle in prostate cancer cells[2]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | Phenoxodiol | ||||||||||||
| CAS | 81267-65-4 | ||||||||||||
| Formula | C15H12O3 | ||||||||||||
| Molar Mass | 240.25 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|